HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Evidence of Reye’s/Nonaspirin Salicylates Link - Procter & Gamble

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble will continue to support Reye's syndrome warnings for bismuth salicylates, provided that such warnings do not imply the ingredient increases risk of the disease

You may also be interested in...



Attapulgite, Polycarbophil Excluded From OTC Antidiarrheal Final Monograph

Activated attapulgite is reclassified from proposed Category I status to nonmonograph in the 1OTC Antidiarrheal Drug Products final monograph, published in the April 17 Federal Register

Bismuth Subsalicylate “Relieves Travelers’ Diarrhea” Claim Proposed by FDA

Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel